Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lisinopril
Drug ID BADD_D01300
Description Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs.[A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844] Lisinopril was granted FDA approval on 29 December 1987.[L8384]
Indications and Usage Lisinopril is indicated for the treatment of acute myocardial infarction, hypertension in patients ≥6 years, and as an adjunct therapy for heart failure.[L8384,L8387] A combination product with hydrochlorothiazide is indicated for the treatment of hypertension.[L8390]
Marketing Status approved; investigational
ATC Code C09AA03
DrugBank ID DB00722
KEGG ID D00362; D08131
MeSH ID D017706
PubChem ID 5362119
TTD Drug ID D07HGR
NDC Product Code 64220-154; 65862-037; 16571-797; 16571-798; 42708-031; 42708-033; 43353-270; 43353-271; 43547-417; 50090-2228; 50090-4678; 51655-707; 53002-1225; 55154-2128; 60687-325; 60760-359; 61919-246; 62135-641; 63187-099; 63629-8823; 65862-039; 65862-040; 65862-042; 68001-336; 68071-5143; 68084-196; 68645-551; 68645-587; 68645-613; 70518-0117; 70518-2600; 71335-0176; 71335-1380; 71610-612; 0615-8254; 76282-419; 76282-729; 0591-0405; 0591-0409; 0904-6797; 0904-7200; 57297-511; 63827-1012; 16729-376; 16729-379; 43353-113; 43353-993; 43547-351; 43547-355; 50090-3763; 51655-146; 55154-8096; 55289-884; 60687-333; 61919-746; 62135-642; 63187-237; 63187-442; 65862-038; 68001-334; 68071-3220; 68180-982; 68645-608; 68645-610; 68788-6407; 70518-1790; 70518-1906; 0591-0406; 71335-0354; 71610-588; 0615-8253; 72865-208; 72865-209; 76282-422; 76282-731; 76282-733; 82009-063; 65862-041; 65977-0009; 23155-714; 31722-172; 42708-142; 43353-301; 50090-3765; 50090-3774; 50090-4725; 50090-4885; 50436-0352; 50436-0354; 51655-399; 51655-729; 51655-999; 58118-1980; 60687-678; 60760-380; 62135-644; 63187-775; 63629-5247; 67296-1202; 67296-1839; 68180-517; 68180-981; 68645-550; 68645-555; 69117-0037; 70882-104; 71205-471; 71335-1295; 71610-624; 0615-8255; 61919-909; 62135-645; 63187-257; 63187-821; 63629-8736; 68001-335; 68180-513; 68645-593; 68788-7012; 68788-7334; 69117-0036; 70518-0544; 70882-103; 70934-155; 71205-180; 71205-742; 71335-0015; 71610-638; 0615-8405; 72865-210; 82009-065; 82982-066; 14593-944; 17404-0011; 16571-794; 16571-795; 42708-154; 43547-418; 43547-419; 50090-0808; 52427-441; 58118-1981; 60760-360; 61919-721; 62135-643; 63187-534; 63629-1761; 67296-1452; 68001-337; 68071-3123; 68645-552; 68645-553; 68645-609; 68788-6820; 68788-6920; 69117-0038; 69117-1003; 70518-1152; 70882-110; 70934-338; 70934-522; 70934-919; 71205-071; 76282-728; 76282-730; 82009-066; 0591-0885; 16571-796; 16729-377; 43063-480; 43063-810; 43063-812; 43547-353; 51655-486; 52427-438; 53002-1123; 60687-646; 60687-667; 63187-825; 68001-332; 68001-486; 68071-3409; 68071-5190; 68180-512; 68180-979; 68180-980; 68645-554; 68645-611; 68788-8351; 70518-0468; 70934-171; 71205-626; 0615-8252; 0904-6800; 67651-0225; 31722-179; 31722-180; 42708-176; 43063-769; 43547-352; 43547-354; 43547-356; 50090-2989; 50090-3175; 51655-995; 52652-3001; 53002-1178; 53002-1463; 60760-358; 60760-390; 60760-438; 61919-717; 61919-736; 63187-098; 63187-780; 68001-333; 68071-2224; 68071-3411; 68084-765; 70518-2561; 70518-2655; 0591-0407; 72789-093; 72789-101; 72865-211; 76282-420; 76282-421; 82009-064; 64220-142; 16729-380; 23155-710; 23155-711; 23155-712; 43063-786; 43063-800; 43063-811; 43063-813; 43353-297; 43353-643; 43353-662; 43353-793; 43547-415; 50090-6303; 51655-335; 51655-411; 52427-442; 62135-640; 63187-722; 68071-3064; 68788-8310; 69117-1001; 71335-0075; 71610-312; 71610-406; 71610-536; 72865-212; 76282-418; 0904-6798; 0904-6799; 65730-1301; 42708-096; 42708-165; 50090-2431; 50090-4887; 52427-443; 55154-4992; 55154-8078; 55700-480; 60760-357; 60760-455; 68645-532; 70518-1156; 70518-1316; 70518-3166; 0591-0408; 76282-417; 16571-799; 16729-375; 31722-176; 31722-178; 42708-032; 43063-074; 43353-009; 43353-298; 43547-414; 43547-416; 50090-5120; 50436-0353; 51655-994; 52427-440; 53002-2123; 55154-2329; 55700-479; 55700-547; 60687-656; 67296-1154; 68645-612; 68788-7666; 69117-1002; 71335-0498; 71335-0536; 72865-213; 76282-732; 82009-062; 16729-378; 23155-713; 23155-715; 31722-177; 42708-094; 43063-814; 43063-815; 52427-439
UNII E7199S1YWR
Synonyms Lisinopril | Lysinopril | Lisinopril Sulfate (1:2) | Prinivil | Zestril | Lisinopril Maleate (1:1) | MK-521
Chemical Information
Molecular Formula C21H31N3O5
CAS Registry Number 76547-98-3
SMILES C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anal incontinence17.05.01.021; 07.01.06.0290.000009%
Speech sound disorder19.19.01.0070.000005%Not Available
Ureterolithiasis20.04.03.0030.000011%Not Available
Anaemia of chronic disease01.03.04.0020.000005%Not Available
Bladder transitional cell carcinoma20.03.04.003; 16.08.01.0020.000007%Not Available
Chronic gastritis11.07.01.016; 10.04.04.011; 07.08.02.0050.000014%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000033%Not Available
Concomitant disease aggravated08.01.03.0630.000009%Not Available
Epiglottic oedema22.04.02.0060.000007%Not Available
IgA nephropathy20.05.01.016; 10.02.01.0630.000009%Not Available
Intestinal villi atrophy07.11.03.0100.000014%Not Available
Cervical radiculopathy17.10.02.0030.000005%Not Available
Tongue biting07.14.01.013; 12.01.17.023; 17.02.05.0640.000009%Not Available
Palatal disorder07.05.01.0190.000005%Not Available
Allergic cough22.02.03.011; 10.01.03.0400.000039%Not Available
Lymphomatoid papulosis23.03.08.0110.000025%Not Available
Palatal oedema07.05.04.0080.000035%Not Available
Subacute cutaneous lupus erythematosus23.03.02.020; 15.06.02.012; 10.04.03.0120.000007%Not Available
Gastrointestinal oedema07.11.01.0120.000010%Not Available
Ulnar nerve palsy17.09.02.0170.000007%Not Available
Acute left ventricular failure02.05.02.0050.000007%Not Available
Charles Bonnet syndrome19.10.04.001; 06.02.06.0160.000007%Not Available
Visceral oedema08.01.07.015; 07.11.01.0310.000009%Not Available
Enlarged uvula07.05.01.0150.000019%Not Available
Skin plaque23.03.03.0440.000005%Not Available
Oral allergy syndrome10.01.01.0330.000023%Not Available
Tubulointerstitial nephritis and uveitis syndrome20.05.02.004; 10.02.01.065; 06.04.03.0060.000009%Not Available
Tongue pruritus07.14.02.0210.000005%Not Available
Lip pruritus07.05.05.0210.000010%Not Available
Psychological trauma19.01.02.0170.000005%Not Available
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene